StockData
CTXRNasdaqPharmaceutical PreparationsFiscal year ends September 30

Citius Pharmaceuticals, Inc.

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.43−0.03 (-7.00%)

Close on Oct 19, 2026

Market cap
$11.20M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Dec 22, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q3 FY2026
Ended Jun 30, 2026
Aug 14, 2026During market hours$1.50M$-0.34–
Q2 FY2026
Ended Mar 31, 2026
May 15, 2026During market hours$1.70M$-0.95–
Q1 FY2026
Ended Dec 31, 2025
Feb 13, 2026Before market open–––
Q4 FY2025
Ended Sep 30, 2025
Dec 23, 2025During market hours–––
Q3 FY2025
Ended Jun 30, 2025
Aug 12, 2025During market hours–$-0.80–
Q2 FY2025
Ended Mar 31, 2025
May 14, 2025During market hours–$-1.27–
Q4 FY2024
Ended Sep 30, 2024
Dec 27, 2024During market hours–––
Q3 FY2024
Ended Jun 30, 2024
Aug 12, 2024During market hours–$-0.06–
Q2 FY2024
Ended Mar 31, 2024
May 14, 2024During market hours–$-0.05–
Q1 FY2024
Ended Dec 31, 2023
Jan 2, 2024During market hours–––
Q3 FY2023
Ended Jun 30, 2023
Aug 15, 2023Before market open–$-0.06–

Press releases

Announcements Citius Pharmaceuticals filed with the SEC